Myocardial perfusion imaging with cadmium-zinc-telluride cameras: Harry Potter and the Radiation Hallows?

Francesco Nudi, MD,^{a,b,c,d} Alessandro Nudi, MD,^a Giuseppe Biondi-Zoccai, MD, MStat,^{e,f} and Orazio Schillaci, MD^g

^a Service of Hybrid Cardio Imaging, Madonna della Fiducia Clinic, Rome, Italy

^b Ostia Radiologica, Rome, Italy

^c Replycare, Rome, Italy

^d ETISAN, Rome, Italy

^e Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy

^f Mediterranea Cardiocentro, Napoli, Italy

^g Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy

Received May 19, 2020; accepted May 19, 2020

doi:10.1007/s12350-020-02267-1

Key Words: Cadmium-zinc-telluride • coronary artery disease • myocardial perfusion imaging • radiation hormesis

See related article, pp. 992–999

Of course it is happening inside your head, Harry, but why on earth should that mean that it is not real?
J.K. Rowling

Ongoing developments in the diagnosis and management of ischemic heart disease require a global reappraisal of practitioners, approach to non-invasive imaging tools, ranging from myocardial perfusion imaging (MPI) to computed tomography angiography (CTA) and cardiac magnetic resonance (CMR).^{1–3} Notwithstanding the need to focus on an integrative approach based on hybrid imaging, capitalizing on the synergy between functional and anatomic imaging tests,

it is important to reconsider a time-tested yet elusive concept, which has many important direct and indirect implications for cardiovascular imaging specialists and practitioners: hormesis.⁴

This term, deriving from the Ancient Greek “to set in motion,” refers to a biological process characterized by an altogether different pathophysiologic dose-response effect, such as low-dose exposure is associated with benefits in comparison to no exposure, whereas high-dose effects are clearly detrimental, notwithstanding the fact that there is no exposure threshold associated with absence of risk.⁵ Visually, hormesis is easily picture as a U-shaped or J-shaped curve, and indeed, this is rather common phenomenon in biology and medicine. Radiation hormesis has been analyzed in great detail, yet several uncertainties persist and is confounded by the established distinction between stochastic and determinist effects of radiation. The typical pathophysiologic framework is that low-dose radiation exposure activates beneficial cellular reparative mechanisms (e.g., autophagy) yielding improved cell function and viability, with corresponding benefits at the tissue, organ, system, and organism level.⁶ Thanks to the study by Baumgarten et al. hereby reported, which highlights the beneficial impact on radiation exposure of myocardial perfusion imaging (MPI) of cadmium-zinc-

Funding This work was supported by Replycare, Rome, Italy, and Etisan, Rome, Italy.

Reprint requests: Francesco Nudi, MD, Service of Hybrid Cardio Imaging, Madonna della Fiducia Clinic, Via Giuseppe Mantellini 3, 00179 Rome, Italy; francesco.nudi@gmail.com

J Nucl Cardiol 2021;28:1000–4.

1071-3581/\$34.00

Copyright © 2020 American Society of Nuclear Cardiology.

Patient A 56-year-old man with multiple cardiovascular risk factors (HTN, NIDDM, smoking) symptomatic for stable angina (CCS III), with normal exercise stress test (normal ST, RRP 27200, maximum workload 10 METs)	Patient B 68-year-old woman with dyslipidemia, symptomatic for dyspnea, with abnormal exercise stress test (2 mm downsloping ST-segment depression at peak, RRP 24320, maximum workload 8.5 METs)
Patient C 49-year-old woman with family history of coronary artery disease, asymptomatic, with high calcium score at coronary computed tomography (Agatston scores: 559 on RCA, 358 on LAD, 288 on LCX, total 1205)	Patient D 71-year-old man with paroxysmal atrial fibrillation, asymptomatic, with 80% diameter stenosis in the proximal LAD involving the first diagonal branch at computed tomography coronary angiography

Figure 1. Baseline features for 4 prototypical patients undergoing stress-only myocardial perfusion imaging with single photon emission computed tomography, highlighting the usefulness of cadmium–zinc–telluride technology given its very high negative predictive value (in terms of both diagnosis and prognosis): patient A—a symptomatic subject with normal stress ECG; patient B—an asymptomatic subject with positive stress ECG; patient C—an asymptomatic subject with elevated coronary calcium score at computed tomography; patient D—an asymptomatic subject with angiographically significant stenosis on the left anterior descending at computed tomography coronary angiography. *CCS*, Canadian Cardiovascular Society; *HTN*, hypertension; *LAD*, left anterior descending; *LCX*, left circumflex; *MET*, metabolic equivalent of task; *NIDDM*, non-insulin-dependent diabetes mellitus; *RCA*, right coronary artery; *RRP*, rate pressure product..

telluride (CZT) cameras, we are happy to introduce provocatively a new concept: clinical hormesis. With clinical hormesis, we envision a framework to analyze the risk/benefit profile of a cardiovascular test (e.g., MPI) or procedure, not as a function of its specific and absolute effect, but rather highlighting its complex dose–response relationship with overall outcomes, considered in a comprehensive framework.⁷

In keeping with radiation hormesis theory and practice, we are all aware that high-dose radiation has clear cytotoxic effects, and thus moderate or severe exposure leads to higher risk of failure or adverse outcomes. Yet, low-dose radiation has beneficial effects, such as mild exposure, and is associated with lower risk, when compared to no exposure at all.⁸ Similarly, in the context of a complex pathophysiologic condition such as coronary artery disease (CAD) leading to ischemic heart disease (IHD), aggressive testing, including multiple and repeat tests with overlapping features, and a low threshold for invasive coronary angiography, is likely

Figure 2. Stress-only myocardial perfusion imaging with single photon emission computed tomography using cadmium–zinc–telluride technology for the same patients described in Figure 1, all showing normal perfusion..

Patient A Warranty period: 4 years	Patient B Warranty period: 3 years
Patient C Warranty period: 2 years	Patient D Warranty period: 1 years

Figure 3. Warranty periods based on the integration of clinical, diagnostic, and imaging results described in Figures 1 and 2, for the same patients thereby described..

associated with overindication to revascularization, poor resource use, and iatrogenic risk, thus amounting to an overall increase in the rate of adverse outcomes in comparison to baseline rate.⁹ Similarly, no testing whatsoever and reliance simply on behavioral and

pharmacologic therapy likely miss the opportunity for optimal selection of patients for revascularization, thus leaving many with adverse clinical and angiographic features (e.g., unprotected left main, severe multivessel disease) at substantial risk of adverse events.¹⁰ Accordingly, appropriately selective use of non-invasive imaging tests (e.g., CTA, CMR, and/or MPI), including their smart integration in a logic of hybrid imaging, may improve patient outlook and reduce risk in comparison to the baseline, thanks to favorable diagnostic and prognostic accuracy, as well as improved decision-making and elucidation of warranty period.^{1,11} Indeed, nuclear medicine in general and nuclear cardiology in particular capitalizes more on the hormesis concept as radiation exposure is not concentrated in a few seconds or minutes, and thus, cellular repairing mechanisms are more capable of adapting appropriately to the corresponding radiologic risk.⁶ This framework is also reinforced by an intuitive application of population attributable risk: as IHD is much more prevalent than radiation-induced cancer, the benefits of clinically appropriate imaging testing with limited radiation exposure clearly outweigh the drawbacks.

This diagnostic hormesis concept is all too relevant in the current era dominated by the late-breaking results of the International Study of Comparative Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial, which randomized more than 5000 patients with moderate or severe ischemia, albeit not universally using an imaging test, to an initial invasive strategy based on invasive coronary angiography vs best medical therapy with invasive assessment reserved to those failing medical therapy or presenting with clinical instability.³ After a median of more than 3 years, event rates were similar in the two groups, despite a trend toward lower risk in the invasive management group, and a significant increase in the rate of spontaneous myocardial infarction in the conservative group.^{3,12} While results of this trial are already subject of intense and hot debate, and their implications will be far reaching, it is clear that putting these two strategies one against the other misses the point of capitalizing on each approach strengths. Indeed, appropriately moderate (i.e., selective) use of invasive testing, following thorough diagnostic and prognostic assessment with a hybrid anatomic and functional cardiac assessment, is evidently posed to minimize the risk of invasive assessment and unnecessary revascularization, while simultaneously improving patient outlook in comparison to a nihilistic and completely conservative clinical management, which reminds us of historical and obsolete clinical practice.¹² Moreover, even admitting that precise characterization of ischemia severity and extent does not improve decision-making for revascularization purposes, it is clear that such assessment

would still benefit patients by means of accurate risk prognostication and definition of warranty period.

Furthermore, even disregarding or refusing altogether the hormesis concept, it is well established that lifetime risk associated with medical radiation exposure is minimal in comparison to many other common risk factors, which range from trauma due to motor vehicles or bicycling, arsenic in drinking water, or home radon exposure.⁸ Yet, all these exposures are socially acceptable despite lacking any beneficial input for medical decision-making. Instead, nuclear cardiology offers detailed data on diagnosis, prognosis, warranty period, and management guidance, often avoiding or minimizing unnecessary radiation exposure due to other downstream tests.¹³ Accordingly, selective application of non-invasive imaging to patients at moderate or high risk of adverse events minimizes any risk and is not only clinically reasonable but ethically mandated, given the necessity to accurately proceed with diagnosis.

Within this broader context, and the renewed perspective of hormesis, we applaud Baumgarten et al. for their comparative diagnostic and clinical study comparing MPI with Anger vs CZT cameras in patients with suspected CAD in a large-volume Brazilian center.⁷ They indeed found that CZT MPI was associated with less radiation exposure acutely, and also when considering all subsequent procedures (thus amounting to indirect radiation exposure as well). Obese patients seemed to benefit less from CZT MPI, with higher exposure acutely and more downstream invasive procedures, but whether this depends on actual drawbacks of CZT technology or on the limitations of Baumgarten and colleagues' non-randomized trial remains to be confirmed, as obesity in itself represents a diagnostic and clinical challenge.¹⁴

In any case, the push toward CZT is supported also by hormesis premises, as this imaging technologies enable physicians to administer much lower doses of radionuclides (even 1/3 of the dose used with Anger cameras).¹¹ Several other advantages of CZT should also be kept in mind, which include the refined imaging quality with ensuing lower risks of false positives and false negatives, the combined appraisal of myocardial perfusion reserve, and the possibility to perform stress-only imaging, thus drastically reducing eventual radiation exposure while yielding high prognostic accuracy, as for instance a negative test is associated with an extremely low rate of adverse cardiovascular events.^{15,16} In these patients, a negative/normal result (in terms of both diagnosis and prognosis) excludes the indication to myocardial revascularization. Accordingly, the association between a non-invasive imaging test result with other clinical and diagnostic features enables the exact definition of a warranty period individualized and

tailored for each patient (Figures 1, 2, and 3). Furthermore, CZT fosters a new age for time-tested thallium, given its optimal kinetics and total flow dependency in comparison to technetium.¹⁷ In addition, thallium remains the gold standard for viability appraisal, for instance, to guide choice between percutaneous and surgical revascularization aimed at viable regions and discarding non-viable ones. Finally, simultaneous imaging with thallium and metaiodobenzylguanidine (MIBG) by means of CZT cameras can identify in patients with recent or prior myocardial infarction the presence of match vs. mismatch of viability (either present or absent) and denervation (either present or absent), and thus optimally guide clinical decision-making in favor or against the use of implantable cardioverter-defibrillators (ICD).¹⁸

In conclusion, in the current ISCHEMIA-dominated era, the role of non-invasive diagnostic testing remains crucial in the diagnostic and prognostic work-up of patients with CAD. Indeed, clinical hormesis postulates that no invasive testing and excessive (i.e., universal) invasive assessment is clearly detrimental to patients and wastes resources, whereas selective invasive assessment based on non-invasive testing (e.g., hybrid imaging compiling MPI with CZT and CTA) is going to substantially reduce short- and long-term risk of adverse outcomes.

Conflict of interest

Drs. Francesco Nudi, Alessandro Nudi and Orazio Schillaci report no conflict of interest. Prof. Giuseppe Biondi-Zoccai has consulted for Replycare.

References

- Biondi-Zoccai G, Versaci F, Iskandrian AE, Schillaci O, Nudi A, Frati G, Nudi F. Umbrella review and multivariate meta-analysis of diagnostic test accuracy studies on hybrid non-invasive imaging for coronary artery disease. *J Nucl Cardiol*. 2018. <https://doi.org/10.1007/s12350-018-01487-w>.
- Biondi Zoccai G, Frati G, Romagnoli E, Sciarretta S, Abbate A. Final results of the ISCHEMIA trial: Distinguishing mass media coverage from clinical interpretation. *Minerva Cardioangiol*. 2020;68:9–14.
- Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamazy A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y, ISCHEMIA Research Group. Initial Invasive Or Conservative Strategy For Stable Coronary Disease. *N Engl J Med*. 2020;382(15):1395–407.
- Shibamoto Y, Nakamura H. Overview of Biological, Epidemiological, and Clinical Evidence of Radiation Hormesis. *Int J Mol Sci*. 2018;19:E2387.
- Baldwin J, Grantham V. Radiation hormesis: Historical and current perspectives. *J Nucl Med Technol*. 2015;43:242–6.
- Martins I, Galluzzi L, Kroemer G. Hormesis, cell death and aging. *Aging (Albany NY)*. 2011;3:821–8.
- Baumgarten R, Cerci R, Costa A, Cunha C, Prado P, Zapparoli M, Masukawa M, Cerci J, Vitola J, Fernandes-Silva M. Keywords: Radiation exposure after myocardial perfusion imaging with cadmium–zinc–telluride camera versus conventional camera. *J Nucl Cardiol* 2020 (in press).
- Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gomes AS, Heller GV, McCollough CH, McNitt-Gray MF, Mettler FA, Mieres JH, Morin RL, Yester MV. Ionizing radiation in cardiac imaging: A science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. *Circulation*. 2009;119:1056–65.
- Weintraub WS, Taggart DP, Mancini GBJ, Brown DL, Boden WE. Historical milestones in the management of stable coronary artery disease over the last half century. *Am J Med*. 2018;131:1285–92.
- Bourantas CV, Papadopoulou SL, Serruys PW, Sakellarios A, Kitslaar PH, Bizopoulos P, Giris C, Zhang YJ, de Vries T, Boersma E, Papafakis MI, Naka KK, Fotiadis DI, Stone GW, Reiber JH, Michalis LK, de Feyter PJ, Garcia-Garcia HM. Non-invasive prediction of atherosclerotic progression: The PROSPECT-MSCT study. *JACC Cardiovasc Imaging*. 2016;9:1009–11.
- Nudi F, Iskandrian AE, Schillaci O, Peruzzi M, Frati G, Biondi-Zoccai G. Diagnostic accuracy of myocardial perfusion imaging with CZT technology: Systemic review and meta-analysis of comparison with invasive coronary angiography. *JACC Cardiovasc Imaging*. 2017;10:787–94.
- Antman EM, Braunwald E. Managing stable ischemic heart disease. *N Engl J Med*. 2020;382:1468–70.
- Shaw LJ, Hachamovitch R, Berman DS, Marwick TH, Lauer MS, Heller GV, Iskandrian AE, Kesler KL, Travin MI, Lewin HC, Hendel RC, Borges-Neto S, Miller DD. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: An observational assessment of the value of precatheterization ischemia. Economics of Non-invasive Diagnosis (END) Multicenter Study Group. *J Am Coll Cardiol*. 1999;33:661–9.
- Patel H, Bhutani S, Posimreddy S, Shah P, Rampal U, Gandhi A, Vasudev R, Pullatt R, Virk H, Shamoony F, Bikkina M, Goldfarb I. The obesity paradox: The protective effect of obesity on right ventricular function using echocardiographic strain imaging in patients with pulmonary hypertension. *Minerva Cardioangiol*. 2018;66:523–7.
- Nudi F, Biondi-Zoccai G, Nudi A, Neri G, Procaccini E, Schillaci O. Comparative analysis between myocardial perfusion reserve and maximal ischemia score at single photon emission computed tomography with new-generation cadmium–zinc–telluride cameras. *J Nucl Cardiol*. 2019 May 31. <https://doi.org/10.1007/s12350-019-01764-2>.
- Alenazy AB, Wells RG, Ruddy TD. New solid state cadmium–zinc–telluride technology for cardiac single photon emission

- computed tomographic myocardial perfusion imaging. *Expert Rev Med Devices*. 2017;14:213–22.
17. Pagnanelli RA, Basso DA. Myocardial perfusion imaging with ^{201}Tl . *J Nucl Med Technol*. 2010;38:1–3.
 18. Blaire T, Bailliez A, Ben Bouallegue F, Bellevre D, Agostini D, Manrique A. First assessment of simultaneous dual isotope (^{123}I /

$^{99\text{mTc}}$) cardiac SPECT on two different CZT cameras: A phantom study. *J Nucl Cardiol*. 2018;25:1692–704.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.